224 related articles for article (PubMed ID: 16253759)
1. Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
Nakamura H; Takamori S; Fujii T; Ono M; Yamana H; Kuwano M; Shirouzu K
Cancer Lett; 2005 Dec; 230(1):33-46. PubMed ID: 16253759
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Jänne PA; Taffaro ML; Salgia R; Johnson BE
Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
[TBL] [Abstract][Full Text] [Related]
4. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
5. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
Tanno S; Ohsaki Y; Nakanishi K; Toyoshima E; Kikuchi K
Oncol Rep; 2004 Nov; 12(5):1053-7. PubMed ID: 15492792
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
[TBL] [Abstract][Full Text] [Related]
7. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
8. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Sirotnak FM; Zakowski MF; Miller VA; Scher HI; Kris MG
Clin Cancer Res; 2000 Dec; 6(12):4885-92. PubMed ID: 11156248
[TBL] [Abstract][Full Text] [Related]
10. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Moasser MM; Basso A; Averbuch SD; Rosen N
Cancer Res; 2001 Oct; 61(19):7184-8. PubMed ID: 11585753
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
[TBL] [Abstract][Full Text] [Related]
13. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab.
Formento P; Hannoun-Levi JM; Fischel JL; Magné N; Etienne-Grimaldi MC; Milano G
Eur J Cancer; 2004 Dec; 40(18):2837-44. PubMed ID: 15571968
[TBL] [Abstract][Full Text] [Related]
14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells.
Chang GC; Hsu SL; Tsai JR; Liang FP; Lin SY; Sheu GT; Chen CY
Biochem Pharmacol; 2004 Oct; 68(7):1453-64. PubMed ID: 15345335
[TBL] [Abstract][Full Text] [Related]
16. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
18. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
Patel D; Bassi R; Hooper A; Prewett M; Hicklin DJ; Kang X
Int J Oncol; 2009 Jan; 34(1):25-32. PubMed ID: 19082474
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
[TBL] [Abstract][Full Text] [Related]
20. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]